CO5690536A2 - Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad - Google Patents

Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad

Info

Publication number
CO5690536A2
CO5690536A2 CO06045059A CO06045059A CO5690536A2 CO 5690536 A2 CO5690536 A2 CO 5690536A2 CO 06045059 A CO06045059 A CO 06045059A CO 06045059 A CO06045059 A CO 06045059A CO 5690536 A2 CO5690536 A2 CO 5690536A2
Authority
CO
Colombia
Prior art keywords
solids
amorph
dispersions
mtp inhibitor
obesity treatment
Prior art date
Application number
CO06045059A
Other languages
English (en)
Spanish (es)
Inventor
Dwayne Thomas Friesen
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5690536A2 publication Critical patent/CO5690536A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
CO06045059A 2003-11-14 2006-05-12 Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad CO5690536A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51993103P 2003-11-14 2003-11-14

Publications (1)

Publication Number Publication Date
CO5690536A2 true CO5690536A2 (es) 2006-10-31

Family

ID=34590458

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06045059A CO5690536A2 (es) 2003-11-14 2006-05-12 Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad

Country Status (16)

Country Link
US (1) US20080293801A1 (https=)
EP (1) EP1696887A1 (https=)
JP (1) JP2007511500A (https=)
KR (1) KR20060096076A (https=)
CN (1) CN1878538A (https=)
AR (1) AR048206A1 (https=)
AU (1) AU2004289110A1 (https=)
BR (1) BRPI0416596A (https=)
CA (1) CA2545443A1 (https=)
CO (1) CO5690536A2 (https=)
IL (1) IL175372A0 (https=)
MX (1) MXPA06005489A (https=)
NO (1) NO20062778L (https=)
NZ (1) NZ546677A (https=)
TW (1) TW200515909A (https=)
WO (1) WO2005046644A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449776T1 (de) 2005-12-15 2009-12-15 Hoffmann La Roche Pyrroloä2,3-cüpyridinderivate
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
CN102781914B (zh) * 2010-01-06 2014-09-17 武田药品工业株式会社 吲哚衍生物
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
US12453728B1 (en) 2024-08-08 2025-10-28 Redux Therapeutics, Llc Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4884235A (en) * 1988-07-19 1989-11-28 Thiele Alfred A Micromagnetic memory package
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
SK287806B6 (sk) * 2001-06-28 2011-10-04 Pfizer Products Inc. Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B)
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

Also Published As

Publication number Publication date
AU2004289110A1 (en) 2005-05-26
JP2007511500A (ja) 2007-05-10
EP1696887A1 (en) 2006-09-06
NO20062778L (no) 2006-08-14
BRPI0416596A (pt) 2007-01-30
KR20060096076A (ko) 2006-09-05
MXPA06005489A (es) 2006-08-11
IL175372A0 (en) 2006-09-05
CN1878538A (zh) 2006-12-13
CA2545443A1 (en) 2005-05-26
TW200515909A (en) 2005-05-16
US20080293801A1 (en) 2008-11-27
AR048206A1 (es) 2006-04-12
NZ546677A (en) 2008-11-28
WO2005046644A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
BRPI0501449A (pt) Mistura funcional, processos para curar e para curar parcialmente uma mistura funcional, e, adesivo
BR0208105A (pt) Inibidores de metaloproteinase
BRPI0710266B8 (pt) composto, medicamento, e, uso de um composto
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
TW200619184A (en) New compound and organic light-emitting device using the same (7)
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
MX2009006846A (es) Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias.
TW200730496A (en) Oxime ester photoinitiators
EP2949644A3 (en) Substituted tetracycline compounds
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
ATE391144T1 (de) Organopolysiloxan und dieses enthaltende härtbare silikonzusammensetzung
BRPI0416440A (pt) processo para a (co)polimerização de etileno
AR082343A2 (es) Un metodo de reduccion de desgaste por rozamiento para combustibles y procedimiento para preparar una composicion combustible
EA200802380A1 (ru) Совместные кристаллы пирролидинонов
CR20130666A (es) Composición de emulsión estable (divisional expediente 9495)
AR043783A1 (es) Difenilazetidinona con propiedades fisiologicas, medicamentos que comprenden este compuesto y su uso
BR0315554A (pt) Dispersões poliméricas com alta estabilidade e processos para sua preparação
CO5690536A2 (es) Dispersiones de solidos amorfos de un inhibidor de la mtp para el tratamiento de obesidad
TW200745027A (en) Novel sulphonylpyrroles
AR060107A1 (es) Inhibidor de polimerizacion para la estabilizacion de monomeros insaturados olefinicamente
ATE453673T1 (de) Ungesättigtes polyesterharz oder vinylesterharz enthaltende zusammensetzungen
BRPI0410540A (pt) protetores e sua aplicação
AR025296A1 (es) MÉTODO PARA INHIBIR LA POLIMERIZACIoN PREMATURA DE MONoMEROS VINIL AROMÁTICOS Y COMPOSICIoN DE MONoMEROS VINIL AROMÁTICOS Y DEL INHIBIDOR.
BR0312608A (pt) Adjuvantes lìquidos
CO5690608A2 (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica